Varicella zoster virus, live attenuated
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2006
- First approval year
- 2006
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Varicella zoster virus, live attenuated
- varicella zoster virus live attenuated component of proquad
- Varicella zoster virus, live attenuated component of proquad
- zostavax
- Zostavax
- varicella zoster virus live attenuated
- varicella zoster virus vaccine zostavax
- Varicella zoster virus, live attenuated
- zostavax
- zostavax concomitant
- zostavax live attenuated herpes zoster vaccine
- zostavax nonconcomitant
- zoster vaccine live zostavax
- ATC classification codes
- J07BK01
Sources for recorded values
- ChEMBL ID
- CHEMBL6068357
- RxNorm IDs (RxCUI)
- 1292422
- First in class
- No
- Orphan designation
- No
- Drug name stem
- vir-
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Chickenpox
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007204
- Subject identifier
- D002644
- Condition identifier
- EFO_0000540
- Condition identifier
- EFO_0006509
- Condition identifier
- EFO_0006510
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007204
- Condition identifier
- MONDO_0005608
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005609
- Condition identifier
- MONDO_0007915
- Highest recorded phase
- 1
- Event
- allergy to vaccine
- Reports
- 12
- Reporting signal score
- 83.649
- Event
- alopecia
- Reports
- 56
- Reporting signal score
- 119.631
- Event
- antibody test negative
- Reports
- 2
- Reporting signal score
- 10.4966
- Event
- arthritis
- Reports
- 17
- Reporting signal score
- 26.9295
- Event
- cataract
- Reports
- 8
- Reporting signal score
- 9.74418
- Event
- cerebral small vessel ischaemic disease
- Reports
- 2
- Reporting signal score
- 7.87476
- Event
- cervical radiculopathy
- Reports
- 2
- Reporting signal score
- 7.76685
- Event
- condition aggravated
- Reports
- 24
- Reporting signal score
- 14.1642
- Event
- diarrhoea
- Reports
- 34
- Reporting signal score
- 10.3834
- Event
- disseminated varicella zoster vaccine virus infection
- Reports
- 2
- Reporting signal score
- 11.5029
- Event
- drug intolerance
- Reports
- 63
- Reporting signal score
- 139.802
- Event
- drug tolerance decreased
- Reports
- 12
- Reporting signal score
- 53.2593
- Event
- dyslipidaemia
- Reports
- 4
- Reporting signal score
- 8.86439
- Event
- expired drug administered
- Reports
- 7
- Reporting signal score
- 26.3452
- Event
- exposure via skin contact
- Reports
- 4
- Reporting signal score
- 17.881
- Event
- extra dose administered
- Reports
- 7
- Reporting signal score
- 16.3893
- Event
- facial paralysis
- Reports
- 4
- Reporting signal score
- 7.80528
- Event
- fungal infection
- Reports
- 6
- Reporting signal score
- 7.69966
- Event
- hepatic cyst
- Reports
- 3
- Reporting signal score
- 7.9799
- Event
- hepatic haematoma
- Reports
- 3
- Reporting signal score
- 12.679
- Event
- hepatitis b core antibody positive
- Reports
- 3
- Reporting signal score
- 13.6957
- Event
- herpes zoster
- Reports
- 74
- Reporting signal score
- 216.072
- Event
- herpes zoster cutaneous disseminated
- Reports
- 3
- Reporting signal score
- 14.7653
- Event
- herpes zoster disseminated
- Reports
- 4
- Reporting signal score
- 16.3958
- Event
- herpes zoster oticus
- Reports
- 2
- Reporting signal score
- 7.8637
And 51 more, listed on the interactive page.
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (85)
- A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
- A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)
- A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)
- A Study of MG1111 in Healthy Children
- A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age
- A Study on the Live-Attenuated Herpes Zoster Vaccine for Sequential Booster Immunization Following Recombinant Herpes Zoster Vaccine
- A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)
- A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)
- A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age
- An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine
- Analysis on AEFI Surveillance Data for Live Attenuated Varicella Vaccine
- Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older
- Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
- Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)
- Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis
- Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age
- Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
- Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines
Approved for (2)
In development for (1)
- Systemic lupus erythematosus Phase 1